The real‐world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies

Pomalidomide‐dexamethasone (Pd) has been a standard care treatment for relapsed and refractory multiple myeloma since 2013. However, the outcomes of Pd after exposure to CD38 antibodies are not known. Here we describe the real‐world use and efficacy of pomalidomide in a Danish, nationwide cohort of...

Descripción completa

Detalles Bibliográficos
Autores principales: Szabo, Agoston Gyula, Thorsen, Jonathan, Iversen, Katrine Fladeland, Levring, Mette Bøegh, Helleberg, Carsten, Hermansen, Emil, Bønløkke, Søren Thorgaard, Nielsen, Katrine, Teodorescu, Elena Manuela, Kurt, Eva, Strandholdt, Casper Nørgaard, Vangsted, Annette Juul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Haematologic Malignancy ‐ Plasma Cell
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660104/
https://www.ncbi.nlm.nih.gov/pubmed/38024635
http://dx.doi.org/10.1002/jha2.774

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660104/
https://www.ncbi.nlm.nih.gov/pubmed/38024635
http://dx.doi.org/10.1002/jha2.774

Ejemplares similares